The cumulative incidence of metachronous BM was calculated by the Kaplan-Meier method, and the independent risk factors of metachronous BM were investigated by multivariate analysis. Comparisons of OS were performed based on BM status. Methods: A total of 157 consecutive EGFR-mutated advanced NSCLC patients without BM at initial diagnosis in our institution from 20 were retrospectively reviewed. The aim of the study was to explore the possible risk factors of developing metachronous BM during EGFR-TKIs treatment, and to identify the potential candidates for prophylactic cranial irradiation (PCI) or the first-line Osimertinib treatment. Reducing BM incidence becomes increasingly significant for NSCLC patients to achieve prolonged survival. Patients with BM are associated with high mortality. Additionally, platinum should not be recommended for treating severely anaemic GC patients.ĪN0144855206 30jul.20 2020Aug01.06:07 v2.2.500 Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancerīackground: NSCLC patients with EGFR mutation were at a higher incidence of developing brain metastasis (BM). Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles.Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. More importantly, HBdec ≥ 30 g/L and treatment response were also significantly associated with OS and PFS. Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. Interestingly, we also found that HBdec ≥ 30 g/L was associated with a significantly shortened median OS and PFS (p = 0.039 and p = 0.001, respectively). Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer-related reduction in haemoglobin was further analysed.Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p = 0.009 and p = 0.049, respectively). Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC.Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Eutron also provides after implementation services, like technical support and repairs through its own national coverage service centers network.Background: Anaemia is highly prevalent in gastric cancer (GC) patients.
![eutron 67586 eutron 67586](https://0.academia-photos.com/attachment_thumbnails/43956910/mini_magick20190215-20797-1975kpq.png)
process analysis, finding the right solution for the identified challenge, customising the solution, implementating it, user training and project management. Our clients benefit from the entire project-specific activity chain, i.e. Eutron creates the necessary solutions for each customer, together with its partners: Datalogic, Zebra, Scantech, TEB, Avery Berkel, Spica, Trassir, Promet, Master Works, Happy-or-Not, Gunebo and many others. Integrated security solutions, fire protection, access control and timekeeping solutions, automatic identification, digital signage and more, help make any manufacturing company more efficient.
![eutron 67586 eutron 67586](https://media.springernature.com/original/springer-static/image/chp%3A10.1007%2F978-3-030-67587-5_9/MediaObjects/481023_1_En_9_Fig2_HTML.png)
Efficiency in the manufacturing activity involves complex projects based on real-time information, its analysis and a computerised decision that eliminates human error. It's hard to imagine manufacturing without process efficiency.